Skip to main content
. 2022 Feb 16;13:904. doi: 10.1038/s41467-022-28520-4

Fig. 5. Selective degradation of pathological aggregation-prone tau species by aggregate-binding AUTOTAC.

Fig. 5

a–c WB in SH-SY5Y-tauP301L cells treated with PBA-1105, PBA, or YTK-1105 at the indicated concentrations. d Densitometry of (a, b, and c) (n = 3 biologically independent experiments). e–g Same as (a–c) but with Anle138b-F105, Anle138b, or YTK-105. (h) Densitometry of (e, f, and g) (n = 3 biologically independent experiments). i WB in SH-SY5Y-tauP301L cells treated with PBA-1105 (0.1 μM) at the indicated time points. j ICC of HeLa cells expressing recombinant TauP301L-GFP and treated with the indicated compounds (1 μM, 24 h) and HCQ (10 μM, 24 h). Scale bar, 10 μm. k Quantification of (j) (n = 3 biologically independent experiments each counting 50 cells). l In vivo oligomerization assay in SH-SY5Y-tauP301L cells treated with okadaic acid (15 nM, 24 h) and the indicated compounds (0.1 μM, 24 h). m Triton X-100-fractionation assay in SH-SY5Y-tauP301L cells treated with a combination of HCQ (10 μM, 24 h), okadaic acid (15 nM, 24 h) or PBA-1105 (0.1 μM, 24 h). Data are presented as mean values ± SD where relevant. P-values (from a two-sided unpaired t test): **P < 0.00821. Source data are provided with this paper.